BioWorld

Jan. 28, 2009

CVT Rejects $1B Acquisition Offer from Partner Astellas

Astellas Pharma Inc. revealed Tuesday that it has spent the last year attempting to acquire CV Therapeutics Inc., but the biotech rejected its latest $1 billion offer and declined to engage in further discussions. (BioWorld Today) Read More

Theravance Files Telavancin NDA for Hospital-Acquired Pneumonia

Obama Election Called End of 'Sad Chapter' for Science

Mixed Bag of Pipeline News for Amgen as Earnings Fall Short

Drugmakers Slow to Personalized Medicine Risk Market Share

UK Report on Start-ups Calls for New Source of Funding

NitroMed Agrees to Deerfield Sale, but also Vows to Shop Around

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...

Illustration of antibody carrying radioactive isotope

Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

BioWorld Science

At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...